Natalizumab for relapsing multiple sclerosis.
Tenser
Richard B
RB
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology*; D016899:Interferon-beta / Q000627:therapeutic use; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4; D016899:Interferon-beta